Taking Sides: Should ob/gyns prescribe flibanserin for their patients?
July 18, 2016A look at the pros and cons of this new drug for women with low sexual desire.
Flibanserin: Risk potential vs. possible benefitBecause of concerns about adverse effects, training through the Addyi REMS program is required for prescribers and pharmacies that want to participate in the medication use process for this drug. Top 5 things to know about “female Viagra” August 20, 2015By Christine BlankFDA’s long-awaited approval of Addyi (flibanserin) to treat hypoactive sexual desire disorder in premenopausal women, is significant for the prescribing community. Urology Product Preview April 2014Drugs and devices in the pipeline from Astellas Pharma, Medivation, Repros Therapeutics, Metamark Genetics, Argos Therapeutics, S1 Biopharma, Ipsen, Sprout Pharmaceuticals, Antigen Express, Generex Biotechnology, Veloxis Pharmaceuticals, and Absorption Pharmaceuticals.